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Abstract
Aims/hypothesis Several glucose-sensing pathways have
been implicated in glucose-triggered secretion of glucagon-
like peptide-1 (GLP-1) from intestinal L cells. One involves
glucose metabolism and closure of ATP-sensitive K+ chan-
nels, and another exploits the electrogenic nature of Na+-
coupled glucose transporters (SGLTs). This study aimed to
elucidate the role of these distinct mechanisms in glucose-
stimulated GLP-1 secretion.
Methods Glucose uptake into L cells (either GLUTag cells
or cells in primary cultures, using a new transgenic mouse
model combining proglucagon promoter-driven Cre recom-
binase with a ROSA26tdRFP reporter) was monitored with
the FLII12Pglu-700μδ6 glucose sensor. Effects of pharma-
cological and genetic interference with SGLT1 or facilitative
glucose transport (GLUT) on intracellular glucose accumu-
lation and metabolism (measured by NAD(P)H autofluor-
escence), cytosolic Ca2+ (monitored with Fura2) and GLP-1
secretion (assayed by ELISA) were assessed.
Results L cell glucose uptake was dominated by GLUT-
mediated transport, being abolished by phloretin but not
phloridzin. NAD(P)H autofluorescence was glucose depen-
dent and enhanced by a glucokinase activator. In GLUTag
cells, but not primary L cells, phloretin partially impaired
glucose-dependent secretion, and suppressed an amplifying
effect of glucose under depolarising high K+ conditions. The
key importance of SGLT1 in GLUTag and primary cells was
evident from the impairment of secretion by phloridzin or
Sglt1 knockdown and failure of glucose to trigger cytosolic
Ca2+ elevation in primary L cells from Sglt1 knockout mice.
Conclusions/interpretation SGLT1 acts as the luminal glu-
cose sensor in L cells, but intracellular glucose concentra-
tions are largely determined by GLUT activity. Although
L cell glucose metabolism depends partially on glucokinase
activity, this plays only a minor role in glucose-stimulated
GLP-1 secretion.
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Glucagon-like peptide-1 (GLP-1) is an incretin hormone
secreted from intestinal L cells, located throughout the gut
epithelium particularly in the ileum and colon [1]. GLP-1
augments insulin secretion in a glucose-dependent manner,
and, together with glucose-dependent insulinotropic poly-
peptide (GIP), is responsible for up to 70% of the insulin
response to food intake in healthy individuals [2, 3]. As
GLP-1 additionally inhibits glucagon secretion, slows gas-
tric emptying and enhances satiety, it is an attractive target
for pharmaceutical interventions. Recent therapies that in-
crease GLP-1 activity, by the use of degradation-resistant
mimetics or inhibition of GLP-1 cleavage by dipeptidyl
peptidase IV, improve glycaemia in patients with type 2
diabetes, demonstrating the success of targeting the GLP-1
axis. Current interest in studying pathways underlying GLP-1
release could lead to new therapeutic strategies for increasing
endogenous GLP-1 secretion.
GLP-1 release is triggered by ingestion of carbohydrates,
fats and protein, and is believed to reflect, at least in part, the
direct sensing of luminal nutrients via the apical processes
of L cells. The release of GLP-1 and GIP after glucose
ingestion accounts for the incretin effect, characterised by
enhanced insulin release triggered by oral compared with
intravenous glucose [4, 5]. This difference can most easily
be explained by a ‘luminal’ glucose sensor, shielded from
variations in the plasma glucose concentration. The identity
of this ‘sensor’ for detecting luminal sugars has been much
debated but not fully elucidated.
Initial studies using the GLUTag cell line suggested that
L cells may use the classical glucose-sensing machinery
used by the pancreatic beta cell, involving glucose phosphor-
ylation by glucokinase, enhanced glycolytic and mitochondri-
al metabolism, and closure of ATP-sensitive potassium (KATP)
channels [6]. More recent studies confirmed that the KATP
channel subunits, Kir6.2 and SUR1, and Glucokinase are
expressed at high levels in purified mouse L cells and that
the proteins are detectable by immunostaining in human
L cells [7–9]. Electrophysiological and secretion studies have
demonstrated that KATP channels are functional in murine
L cells and that sulfonylureas can stimulate GLP-1 secretion
from primary colonic cultures [7].
An element of glucose sensing by L cells is, however,
clearly independent of metabolism, as GLP-1 secretion is
also stimulated by non-metabolisable sugars such as methyl-
α-glucopyranoside (αMG) and 3-O-methylglucose in whole
animals [10], intestinal preparations [11], GLUTag cells and
primary intestinal cultures [7, 12]. Early in vivo studies
showed that luminal sugar stimulation of GLP-1 secretion
is Na+ dependent and that the specificity of the response
paralleled the sugar specificity of Na+-coupled glucose
transport [11, 13]. This led to the identification of a distinct
glucose-sensing pathway in L cells, resulting from the ac-
tivity of Na+-coupled glucose transporters (SGLTs) [12].
These concomitantly carry Na+ ions for each glucose mol-
ecule transported, thereby generating small depolarising
currents sufficient to trigger electrical activity and Ca2+
entry and consequent increased GLP-1 secretion.
As the relative importance of SGLTs, intracellular glu-
cose levels and metabolism for glucose-dependent GLP-1
secretion is unclear, we aimed to further investigate the roles
of these mechanisms in determining L cell glucose fluxes
and GLP-1 release.
Methods
Animal models Animal procedures were approved by the
local ethics committee and conformed with UK Home Office
regulations. Sglt1−/− mice [14] on a C57BL/6 background
were crossed with GLU-Venus transgenic mice [7]. Sglt1−/−
and Sglt1+/+ littermates received a glucose/galactose-reduced
diet (Altromin, Lage, Germany).
Labelling of intestinal L cells with a red fluorescent
protein (RFP) was achieved by crossing Rosa26tdRFP report-
er mice [15] with mice expressing Cre recombinase under the
control of the proglucagon promoter (GLU-Cre12 mice).
GLU-Cre12 mice were created using a construct based on
the bacterial artificial chromosome (BAC) RP23-343C17
(Children’s Hospital Oakland Research Institute, Oakland,
CA, USA) in which the sequence between the proglucagon
start codon in exon 2 and the stop codon in exon 6 was
replaced by iCre using Red/ET recombination technolo-
gy (Genebridges, Heidelberg, Germany) (see electronic
supplementary material [ESM Methods/Table 1] for more
details).
Tissue culture Intestines from 3- to 6-month-old mice were
collected, and the epithelial cells cultured as described previ-
ously [7]. The upper (∼top third) small intestine (SI) com-
prised a 10 cm length distal to the stomach, and the colon was
taken distal to the ileocolic junction. Aliquots were plated on
to 24-well plates or 35 mm glass-bottomed dishes (MatTek,
Ashland, MA, USA) coated with Matrigel (BD Biosciences,
Oxford, UK) for 24–48 h and incubated at 37°C in 5% CO2.
GLUTag cells were cultured as described previously [16, 17].
Intracellular glucose measurements The FLII12Pglu-
700μδ6 Förster resonance energy transfer (FRET) glucose
sensor [18] was cloned into pShuttle-CMV (Qbiogene,
Carlsbad, CA, USA) for generation of adenoviruses [19].
GLUTag cells were transfected with pcDNA3.1 containing
the glucose sensor under cytomegalovirus (CMV) promoter
control (Addgene, Cambridge, MA, USA), using Lipofect-
amine 2000 (Invitrogen, Paisley, UK). Cells were then seeded
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on to Matrigel-coated glass-bottomed dishes and imaged 24–
48 h later. Before imaging, GLUTag cells were incubated in
saline buffer (see below) for 10 min at room temperature. Two-
day-old primary colonic cultures from GLU-Cre-×−tdRFP
mice were transduced with adenovirus encoding the
FLII12Pglu-700μδ6 glucose sensor and imaged 72 h later.
Before each experiment, colonic cultures were incubated in
forskolin (10 μmol/l) and 3-isobutyl-1-methylxanthine
(100 μmol/l) for 30 min at 37°C. L cells were identified by
their RFP fluorescence and characteristic morphology. FRET
imaging was performed using an inverted fluorescence micro-
scope (Nikon Eclipse TE2000-S or Olympus IX71) with a×40
oil immersion objective. The FRET probe was excited
every 5 s at 434/10 nm using a 75 W xenon arc lamp and
monochromator (Cairn Research, Faversham, UK) controlled
by MetaFluor software (Molecular Devices, Wokingham,
UK). Emission was recorded with a CCD camera (QuantEM
Photometrics, Tucson, AZ, USA or Orca-ER, Hamamatsu
Photonics, Welwyn Garden City, UK) behind an Optosplit II
image splitter (Cairn Research) equippedwith cyan fluorescent
protein (CFP) and yellow fluorescent protein (YFP)
emission filter sets. Fluorescence was recorded from individ-
ual cells, background corrected and expressed as the ratio
YFP/CFP. For analysis, data were averaged over 15–20 s,
and peak responses normalised by dividing by the pretreat-
ment baseline.
Immunohistochemistry Tissues were fixed with 4% (w/v)
paraformaldehyde for 24 h, cryoprotected in 30% sucrose
and embedded in Optimal Cutting Temperature compound
(OCT; CellPath, Newton, UK). Tissue sections (8 μm) were
permeabilised with 0.05% Tween, blocked with 3% BSA for
1 h, and incubated with 1:300 diluted glucagon antibody
(catalogue no. sc-13091, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or 1:50 diluted Glut2 antibody (catalogue
no. sc-7580; Santa Cruz) overnight at room temperature.
Tissues were then incubated for 1 h at room temperature
with Alexa 488-conjugated goat anti-rabbit antibody or
donkey anti-goat Alexa Fluor 633 (1:300 dilution; Invitrogen)
and Hoechst stain. Tissue samples stained with secondary
antibody alone served as controls. Images were captured using
either an inverted fluorescence (Olympus IX71) or confocal
(Zeiss LSM510) microscope and processed using Volocity
and MetaFluor software.
Assay of glucokinase activity Glucokinase activity was de-
termined using an adapted pyridine nucleotide-coupled assay
[20]. Briefly, ∼3×107 GLUTag cells were homogenised in
buffer containing (in mmol/l) 25 Hepes, 150 KCl, 2 dithio-
threitol and 1 EDTA (pH 7.4), and the resultant supernatant
fraction was mixed with assay buffer containing (in mmol/l)
100 Hepes, 6 MgCl2, 5 ATP, 0.1% BSA, 150 KCl, 1 dithio-
threitol, 1 β-NAD, 0.045 5-thio-D-glucose 6-phosphate,
1 3-O-methyl-N-acetylglucosamine (Axxora, Exeter, UK),
2.5 IU/ml glucose-6-phosphate dehydrogenase from Leuco-
nostoc mesenteroides and glucose (0–60 mmol/l) in a 96-well
plate. NADH fluorescence (excitation 320 nm, emission
460 nm) was measured every 1 min for 2 h at 30°C using a
Fluoroskan Ascent plate reader (Thermo Scientific, Basing-
stoke, UK).
NAD(P)H imaging in GLUTag cells NAD(P)H levels were
imaged in GLUTag cells cultured for 24–48 h on Matrigel-
coated glass-bottomed dishes. Cells were washed with and
incubated in saline buffer for ∼15 min, mounted on an
Olympus IX71 microscope with ×40 oil-immersion objec-
tive, and imaged using an Orca-ER CCD camera and Meta-
fluor software. Cells were perfused with saline buffer (plus
glucose as indicated) at room temperature. Autofluores-
cence at 360/15 nm excitation, 510/80 nm emission, was
measured every 10 s, background corrected, and averaged
over 60 s periods. Mean fluorescence under test conditions
was normalised by dividing by the mean of baselines mea-
sured before addition, and after washout, of the test reagent.
Analysis of primary L cells by flow cytometry Single-cell
digests were fixed with 4% paraformaldehyde in PBS for
30 min at room temperature and blocked with PBS/10%
goat serum at 4°C overnight. Cells were permeabilised with
0.1% vol./vol. Triton X-100 in PBS/10% goat serum for
30 min at room temperature, and then incubated with or
without primary antibody detecting proglucagon (source as
above; 1:200 dilution) in PBS/10% goat serum at room
temperature for 3 h. Cells were rinsed three times in PBS/
10% goat serum and incubated for 1 h with secondary
antibody (Alexa Fluor 488; Invitrogen, Eugene, OR, USA;
catalogue no. A-11034 at 1:300 dilution). After three washes
with PBS, cells were analysed using a BD LSRFortessa
analyser (BD Biosciences, San Jose, CA, USA) equipped
with 488 nm and 561 nm lasers for excitation of Alexa Fluor
488 and RFP, respectively. Data were analysed using
FlowJo 7.6 software (Tree Star, Ashland OR, USA).
For NAD(P)H measurements from primary L cells, SI
tissue from GLU-Venus mice was digested to single cells [7]
and analysed on the same day. Cells were washed and
resuspended in saline buffer containing 0.1% BSA and
various glucose concentrations (0–30 mmol/l) 10–15 min
before analysis. From each condition, 106 events were
assessed using an LSRFortessa analyser and FlowJo 7.6
software. Venus-positive L cells were selected on the basis
of their characteristic fluorescence when excited at 488 nm,
and autofluorescence was assessed by excitation at 355 nm
(emission 450 nm). The geometric mean of the 355 nm
fluorescence intensity distribution from each cell population
was calculated and normalised to that of the zero glucose
control measured on the same day.
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Small interfering RNA (siRNA) knockdown GLUTag cells
were transfected with 50 nmol/l scrambled or Sglt1 siRNA
(Qiagen, Crawley, UK) for 24 h using Lipofectamine 2000.
Cells were reseeded into 24-well plates and used 24 h later.
Knockdown efficiency was assessed using Taqman assays
for Slc5a1 (sglt1) and Actb (β-actin) (Applied Biosystems,
Paisley, UK) [7, 21].
GLP-1 secretion Secretion studies on GLUTag and primary
intestinal cultures were performed 24–36 h after plating in
Matrigel-coated 24-well plates. Cultures were incubated
with test reagents in saline buffer containing 0.1% fatty
acid-free BSA for 2 h at 37°C. Cell lysates were then
collected from primary cultures as described previously
[7]. Supernatant fractions and lysates were assayed using
either a GLP-1-active ELISA kit (Millipore, Watford, UK)
or a total GLP-1 assay (MesoScale Discovery, Gaithersburg,
MD, USA). For primary cells, GLP-1 secretion was
expressed as a fraction of the total hormone content per
well, normalised to basal secretion measured in parallel.
For GLUTag cells, supernatant fraction concentrations were
normalised to basal levels in parallel control wells.
Calcium imaging Experiments were performed on 5- to 8-
day-old cultures from Sglt1−/− mice and wild-type litter-
mates, crossed into the GLU-Venus background. Cells were
loaded in 7 μmol/l fura2-AM (Invitrogen, UK) and 0.01%
pluronic F127, and incubated in saline buffer containing
1 mmol/l glucose and 300 μmol/l eserine, for 30 min.
Experiments were performed using the Olympus IX71 im-
aging system described above. Fura2 was excited at 340 and
380 nm (emission 510/80 nm), andVenus at 475 nm (emission
535/50 nm). Fura2 fluorescence measurements were taken
every 2 s, background corrected, and expressed as the 340/
380 nm ratio. Mean fluorescence ratios were determined over
20 s, and responses expressed as the maximum ratio achieved
during stimulation divided by the mean of the ratios measured
before and after washout. Cells were included in the analysis if
they responded to the positive controls, 10 mmol/l glutamine
and 30 mmol/l KCl.
Solutions Saline buffer contained (mmol/l) 4.5 KCl, 138
NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2
and 10 HEPES (pH 7.4, NaOH). In some experiments, KCl
was increased with equivalent reduction in NaCl, in others
Na+ was replaced by N-methyl-D-glucamine (NMDG).
Where possible, solutions were prepared as ×1,000 stock.
Glucokinase activator (GKA50) [22] (AstraZeneca, Maccles-
field, UK) was dissolved in DMSO. Chemicals were supplied
by Sigma Aldrich (Poole, UK) unless otherwise stated.
Data analysis Data are presented as means±SEM. Signifi-
cance was assessed using Student’s t test (Microsoft Excel)
or by one- or two-way ANOVA followed by Bonferroni or
Dunnett’s post hoc tests (Graph Pad Prism Software, San
Diego, CA, USA). p<0.05 was considered significant.
Results
Glucose uptake pathways in L cells Intracellular glucose
levels were monitored in GLUTag cells transiently produc-
ing the FLII12Pglu-700μδ6 glucose FRET probe [18]. Initial
experiments confirmed the specificity of the sensor, as glu-
cose (1 or 10 mmol/l), but not glutamine (10 mmol/l) or the
glucose analogue αMG (10 mmol/l), elicited a significant
increase in the YFP/CFP ratio (Fig. 1a,b). To determine
whether glucose entry into L cells is primarily mediated by
Na+-coupled (SGLT) or facilitative (GLUT) glucose trans-
port, we examined the effects of extracellular Na+ replace-
ment and pharmacological inhibitors of both classes of
transporter (Fig. 1c–e). The response to 10 mmol/l glucose
was impaired in the presence of 1 or 5 μmol/l phloridzin, but
appeared increased rather than decreased in the absence of
Na+. Although the increased glucose signal following Na+
substitution could reflect a paradoxical increased net glu-
cose influx, it might also be caused by a reduced rate of
glucose metabolism or an altered intracellular ionic compo-
sition/pH affecting the properties of the glucose sensor. A
robust inhibition of glucose uptake was observed in the
presence of either phloretin (10 or 100 μmol/l) or cytocha-
lasin B (10 μmol/l), both of which target the GLUT family.
As we previously reported an ∼10-fold higher expression
of Sglt1 mRNA in primary L cells compared with GLUTag
cells [7], we aimed to perform similar experiments in L cells
in primary culture. To enable the use of YFP/CFP-based
FRET sensors, we developed a mouse model in which
L cells are identifiable by their red fluorescence. Transgenic
mice were generated in which Cre-recombinase expression
is driven by the proglucagon promoter (GLU-Cre12). Cross-
ing these with Rosa26tdRFP reporter mice [15] resulted in
red fluorescence in glucagon-positive pancreatic alpha cells
(Fig. 2a) and GLP-1-containing L cells (Fig. 2b), as
expected. The efficiency of L cell targeting was quantified
by FACS analysis of colonic epithelial cell suspensions
from GLU-Cre12×tdRFP mice, revealing that >70% of
proglucagon-positive cells had undergone Cre-mediated re-
combination (Fig. 2c–e). We detected a fraction of cells
(<30%) with red fluorescence not staining for proglucagon,
corresponding to a small number of red fluorescent cells in
primary colonic cultures not showing the typical morphology
of L cells. These were excluded morphologically from experi-
ments on mixed epithelial primary cultures transduced with a
newly made adenovirus expressing FLII12Pglu-700μδ6. In
L cells in primary culture, 10 mmol/l glucose elicited an
average 1.34-fold increase in the YFP/CFP ratio, which was
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abolished by phloretin (100 μmol/l) but unaffected by phlor-
idzin (5 μmol/l) (Fig. 2f,g). The glucose transporter GLUT2
was detected in the basolateral membrane of enterocytes and
L cells (Fig. 2h).
Glucose-stimulated changes in L cell metabolism To inves-
tigate whether elevation of intracellular glucose translates
into metabolic changes within GLUTag cells, we monitored
the autofluorescence signal attributed to NAD(P)H by real-
time imaging (Fig. 3a). Glucose dose-dependently increased
NAD(P)H autofluorescence, eliciting a maximal 1.8-fold
increase at 10 mmol/l (Fig. 3b). To monitor NAD(P)H in
primary L cells, we developed a FACS analysis-based tech-
nique for use with acutely dispersed SI epithelial cells. In the
Venus-labelled L cell subpopulation, glucose dose-dependently
shifted the histogram of NAD(P)H autofluorescence rightwards
(Fig. 3 c,d).
Role of glucokinase in L cells To examine the role of the
gene encoding glucokinase (Gck), which is expressed in
GLUTag and L cells at mRNA levels comparable to those
found in pancreatic beta cells [7], we measured enzyme
activity in GLUTag cell extracts [20]. Consistent with func-
tional glucokinase production, the enzymatic rate increased
with increasing glucose concentrations in the mmol/l range,
at which low-affinity hexokinases would be saturated, and a
significant (p<0.001) further increase was observed when a
glucokinase activator, GKA50 (3 μmol/l), was added to the
cell extract (Fig. 4a). Addition of GKA50 to 3 mmol/l glu-
cose also significantly increased the NAD(P)H autofluores-
cence in GLUTag cells (Fig. 4b). In secretion experiments,
GKA50 caused a small but significant increase in glucose-
stimulated GLP-1 release from GLUTag cells (p<0.01 by
two-way ANOVA, Fig. 4c). However, under the conditions
tested, we were unable to detect an effect of GKA50 on
GLP-1 secretion from primary intestinal cultures (Fig. 4d).
Effect of intracellular glucose on GLP-1 secretion To eval-
uate whether glucose-dependent GLP-1 release requires ac-




















































































































Fig. 1 Glucose uptake into GLUTag cells. (a) Representative trace
showing the raw FRET YFP/CFP ratio monitored in a single GLUTag
cell producing FLII12Pglu-700μδ6. Glucose (10, 1, 0.1 mmol/l) was
applied as indicated by the horizontal bars. (b) Mean normalised YFP/
CFP ratio, recorded as in (a). Glucose (0.1, 1 or 10 mmol/l, applied in
random order), αMG (10 mmol/l) and glutamine (Gln, 10 mmol/l)
were applied as indicated. Error bars represent 1 SEM from n06–16
cells as indicated above the bars from two to four separate experiments.
(c) Mean normalised YFP/CFP ratio, recorded as in (a), elicited by
10 mmol/l glucose applied in saline buffer (Na+ +) or after Na+
substitution by NMDG+ (Na+ −) in n015 cells as indicated above the
bars. (d) Representative trace, recorded as in (a). Glucose (10 mmol/l),
phloretin (Phlt, 100 μmol/l), phlorizdin (Phlz, 1 μmol/l) or cytochala-
sin B (Cyt B, 10 μmol/l) was applied as indicated. (e) Mean normalised
YFP/CFP responses, recorded as in (d), to glucose (10 mmol/l), phlor-
idzin (Phlz, 1, 5 μmol/l), phloretin (Phlt, 10, 100 μmol/l) or cytocha-
lasin (CytB, 10 μmol/l) in n020–29 cells as indicated above the bars
from five to seven separate experiments. Statistical significance was
tested by ANOVA followed by a Student’s t test to compare responses
to baseline (*p<0.05, **p<0.01, ***p<0.001) or by Dunnett’s test to
compare responses to glucose (†††p<0.001)
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from glucose metabolism, we examined whether GLUT
inhibition, which largely abolished intracellular glucose
transients, affected GLP-1 secretion. In primary intestinal
cultures, the secretory response to 1 mmol/l glucose was not
significantly impaired by phloretin (10 or 100 μmol/l),
whereas the higher dose abolished secretion from GLUTag
cells (Fig. 5a,b). In contrast, in both model systems,
glucose-triggered secretion was significantly reduced when
SGLTs were inhibited by phloridzin, with more profound
effects evident in the primary cultures (Fig. 5 a,b). Consistent
with a dominant role of electrogenic Na+-coupled glucose
uptake in primary L cells, no further glucose-dependent
increase in GLP-1 secretion was observed in primary cultures
depolarised by KCl (Fig. 5c). Glucose-dependent amplifica-
tion of secretion was, however, seen under these conditions in
GLUTag cells (Fig. 5d), which was sensitive to phloretin but
not phloridzin (Fig. 5e).
Role of SGLT1 in glucose-triggered GLP-1 secretion To
further confirm the role of SGLT1 in glucose-stimulated
GLP-1 secretion, we crossed GLU-Venus mice with the
recently described Sglt1 knockout mouse model [14]. Glu-
cose (10 mmol/l) triggered a rise in cytosolic Ca2+ in iden-
tified L cells in colonic cultures from Sglt1+/+ but not
Sglt1−/− mice (Fig. 6a,b). Glutamine, in contrast, stimulated
similar Ca2+ responses in L cells from both wild-type and
knockout tissue cultures. This is consistent with the previous
observation that Sglt1 knockout selectively abolishes
glucose-stimulated GLP-1 secretion [14].
As the impaired Ca2+ response and GLP-1 secretion of
L cells in this SGLT1-deficient model may still arise from a
defect in glucose uptake into neighbouring cells rather than
the enteroendocrine cells themselves, we also knocked
down Sglt1 in GLUTag cells using siRNA, which decreased
mRNA expression by ∼60% (Fig. 6c). Sglt1 knockdown
largely abolished the effects of both glucose (10 mmol/l)
and αMG (100 mmol/l) on GLP-1 release (Fig. 6d).
Discussion
The mechanism underlying glucose sensing by L cells is a
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Fig. 2 Mechanisms of glucose uptake in primary L cells. (a,b) Coloc-
alisation of direct tdRFP fluorescence (red) with glucagon immunoflu-
orescence (green) in (a) pancreatic and (b) colonic tissue slices from a
GLU-Cre12×tdRFP mouse. Blue represents Hoechst fluorescence. (c)
FACS analysis performed on colonic digests from GLU-Cre12×tdRFP
mice stained with an antibody against proglucagon and a green fluo-
rescent secondary antibody. Frequency histograms represent the green
fluorescence of all tdRFP-positive cells (dark grey shading) or all
strongly green fluorescent cells (tdRFP-positive and -negative cells;
light grey shading). The non-shaded distribution represents the green
fluorescence of tdRFP-positive cells when primary proglucagon anti-
body was omitted. Frequencies are given in arbitrary units (AU). (d,e)
FACS-determined percentages of tdRFP-producing cells staining for
proglucagon (d), and of proglucagon-positive cells that contain tdRFP
from three independent experiments. (f) Intracellular glucose, moni-
tored as YFP/CFP ratio, in individual primary L cells identified by
tdRFP fluorescence. Glucose (10 mmol/l), phloridzin (5 μmol/l) or
phloretin (100 μmol/l) was applied as indicated. (g) Mean normalised
FRET responses, recorded as in (f) from n06–20 cells (as indicated
above the bars) from more than five separate experiments. *p<0.05,
***p<0.001 vs baseline by single-factor t tests. Statistical comparison
between glucose and other conditions was assessed by ANOVA and
Dunnett’s test; †††p<0.001. (h) Immunofluorescent localisation of
GLUT2 in a duodenal slice. Left, phase-contrast image of a villus,
with superimposed Venus fluorescence (green) identifying an L cell;
middle, GLUT2 immunofluorescence (red); right, overlay of Venus
fluorescence and GLUT2 immunofluorescence
R
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[23, 24], SGLT1 [12] and KATP channels [16] each sug-
gested to play a role. We demonstrate here that genetic or
pharmacological interference with SGLT1 abolishes
glucose-triggered Ca2+ responses and GLP-1 secretion from
L cells in primary culture. This is consistent with the inhi-
bition of GLP-1 secretion by phloridzin from perfused in-
testinal preparations [10] and the more recent observation of
impaired glucose-triggered GLP-1 secretion in Sglt1 knock-
out mice [14]. The latter observations are incompatible with
the concept of an apically located glucose receptor on the
surface of the L cell, as inhibition of glucose absorption
would, if anything, tend to increase exposure of such a recep-
tor to luminal glucose. Although they could be explained by a
basolaterally expressed receptor which is exposed to elevated
glucose concentrations after SGLT1-dependent absorption
through enterocytes, the current findings, in which both sides
of the cells are exposed to glucose, argue against any major
role of an extracellular receptor. This is consistent with our
previous observation that artificial sweeteners, at concentra-
tions that saturate Tas1R2/3 receptors, did not trigger GLP-1
release from primary intestinal cultures [7]. A metabolic sens-
ing mechanism downstream of SGLT1-mediated glucose up-
take could also be envisioned. Monitoring intracellular
glucose levels, however, allowed us to dissociate the stimula-
tory action of Na+-coupled glucose uptake from possible
downstream metabolic effects, as SGLT inhibition had only
minor effects on intracellular glucose levels, whereas GLUT
inhibitors largely abolished glucose uptake in L cells but did



















































































































Fig. 4 Role of glucokinase in GLUTag and primary L cells. (a)
Glucokinase activity in GLUTag extracts vs glucose concentration in
the absence (black squares, solid line) and presence (white circles,
dotted line) of GKA50 (3 μmol/l). Velocity represents the increase in
fluorescence over time in arbitrary units (AU). Data were fitted using a
hyperbola plot with the equation y0vmax[glucose]/(S0.5 + [glucose]),
giving values of 3 and 1 mmol/l for S0.5, the substrate concentration at
which half the maximal velocity (Vmax) is reached, in the absence and
presence of GKA50, and Vmax under both conditions of 0.07 AU (n04).
(b) Mean normalised NAD(P)H autofluorescence responses in GLUTag
cells after addition of glucose (3 mmol/l) and GKA50 (3 μmol/l). n054
cells from three separate experiments. Statistical comparison to autofluor-
escence in the absence of glucose (***p<0.001) and between the ab-
sence/presence of GKA50 (†††p<0.001) were assessed by Student’s
t test. (c) GLP-1 secretion from GLUTag cells in response to various
concentrations of glucose, with GKA50 (3 μmol/l, black bars) or without
GKA50 (white bars). Secretion was normalised to parallel baseline meas-
urements and the number of wells is shown above the bars. Statistical
comparisons were assessed by two-way ANOVA (p00.0047 for GKA50
vs no GKA50, and p<0.0001 for effect of glucose concentrations, with
no significant interaction), followed by post hoc Bonferroni’s test;
***p<0.001 vs respective controls in the absence or presence of
GKA50. (d) GLP-1 secretion from primary upper SI cultures in response
to 1 mmol/l glucose with or without GKA50 (3 μmol/l). Secretion was
calculated relative to GLP-1 content, normalised to basal secretion mea-
sured in parallel, with the number of wells given above the bars. Signif-

























































































Fig. 3 Glucose-dependent changes in L cell metabolism. (a) Repre-
sentative trace representing NAD(P)/NAD(P)H autofluorescence (ar-
bitrary units, AU) from a GLUTag cell upon glucose application (0.1,
1, 10, 25 mmol/l). (b) Mean normalised autofluorescence, recorded as
in (a). n081 cells from five separate experiments. (c) Smoothed fre-
quency histograms showing the autofluorescence intensity of primary
L cells in small intestinal digests in the absence (white-shaded) and
presence (dark grey-shaded) of 10 mmol/l glucose. For each condition,
1 million events were counted, of which ∼0.1% were Venus positive.
(d) Normalised mean autofluorescence intensities of primary L cells,
analysed as in (c), from four to five mice analysed independently as
indicated above the bars. *p<0.05, **p<0.01, ***p<0.001 vs baseline,
by Student’s single-sample t test
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Sglt1 knockdown in GLUTag cells impaired both glucose-
andαMG-triggered secretion argues for a mechanism intrinsic
to the enteroendocrine cells, rather than involving coupling
through neighbouring enterocytes. It also demonstrates a
dominant role of SGLT1 over SGLT3, which is also produced
in GLUTag and primary L cells [7]. We thus conclude that the
electrogenic uptake itself via apically localised SGLT1 [7] is
the major glucose-sensing mechanism in L cells.
To enable the use in primary tissues of FRET-based
sensors employing YFP and CFP, we generated a new
BAC transgenic mouse model expressing the gene encoding
Cre recombinase under control of the proglucagon promoter,
targeting enteroendocrine L cells as well as pancreatic alpha
cells unlike the shorter promoter constructs used previously to
drive Cre expression in alpha cells [25]. Quantification by
FACS analysis revealed that, although the majority of
proglucagon-stained cells in the colon also contained the Cre
reporter in GLU-Cre12×tdRFP mice, ∼30% did not. This
suggests that a small but significant number of L cells may
escape Cre recombination, and should be taken into account
when GLU-Cre12 mice are used in future conditional gene
knockout experiments. Cre-mediated activation of RFP pro-
duction was also evident in some cells that did not stain for
proglucagon, consistent with the observation that a small
proportion of the red fluorescent cells in primary colonic
cultures did not exhibit morphology typical of L cells. These
cells were readily identifiable and could be avoided in single-
cell imaging experiments, but are likely to reflect transient
transgene activation in a different cell population during de-
velopment. Similar findings in the other founder GLU-Cre
strains (see ESM Table 2) suggest that this is not merely an
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Fig. 5 Pharmacological modulation of glucose-stimulated GLP-1 se-
cretion. GLP-1 secretion from (a) GLUTag cells and (b) primary upper
SI cultures, in glucose (1 mmol/l), phloretin (Phlt, 10 or 100 μmol/l)
and phloridzin (Phlz, 1 or 5 μmol/l), as indicated. Incremental
responses to glucose are shown for each condition, normalised to the
incremental glucose response in the absence of inhibitor (100%). Error
bars represent 1 SEM and the number of wells is given above the bars.
Significance was assessed by one-way ANOVA and Dunnett’s test vs
glucose only; **p<0.01, ***p<0.001. (c) GLP-1 secretion from pri-
mary upper SI cultures in 30 or 70 mmol/l extracellular K+ and
340 μmol/l diazoxide (Diaz) in the absence (white bars) or presence
(black bars) of glucose (1 or 10 mmol/l) as indicated. Error bars
represent 1 SEM and the number of wells is given above the bars.
Secretion was calculated relative to GLP-1 content and normalised to
basal secretion measured in parallel. (d,e) GLP-1 secretion from GLU-
Tag cells in 30 mmol/l extracellular K+ and 340 μmol/l diazoxide and
(d) various glucose concentrations or (e) 1 mmol/l glucose with or
without phloretin (10 μmol/l, Phlt) or phloridzin (5 μmol/l, Phlz) as
indicated. Secretion was normalised to baseline secretion measured in
parallel. Error bars represent 1 SEM and the number of wells is given
above the bars. Significance was determined by one-way ANOVA
followed by one-sample t tests and Dunnett’s test vs glucose in the
absence of inhibitor; *p<0.05, **p<0.01, ***p<0.001
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Previous analysis detected Glut1, Glut2 and Glut5 ex-
pression in primary murine L cells, with Glut2 evident in
L cells from the SI, and Glut1 in those from the colon [7].
GLUTag cells notably lack Glut2 [12], but express Glut3, as
determined by Affymetrix microarrays (data not shown).
The role of GLUTs in incretin hormone secretion is unclear,
as their pharmacological inhibition had no significant effect
on glucose-stimulated GLP-1 secretion in primary cultures,
although mice lacking GLUT2 showed reduced plasma
GLP-1 concentrations following oral glucose, and a lower
intestinal GLP-1 content [26]. Whereas SGLT1 is apically
located on L cells [14], GLUT2 appeared localised to the
basolateral surface of L cells and enterocytes, suggesting
that intracellular glucose concentrations would reflect baso-
lateral rather than luminal glucose levels. Whereas GLP-1
secretion is predominantly stimulated by oral rather than
systemic glucose delivery, GLP-1 release from the perfused
pig intestine was found to be influenced also by vascular
glucose levels [27], possibly through alteration of the intra-
cellular glucose concentration in L cells.
Whether intracellular glucose metabolism plays any role
in determining GLP-1 secretion remains uncertain. In GLU-
Tag but not primary L cells, we observed a strong inhibition of
secretion when glucose uptake was completely blocked and
an amplifying action of glucose under depolarising condi-
tions. The balance between the metabolic and electrogenic
effects of glucose is thus slightly different between the cell
line and primary culture, with a more dominant role for
SGLT1-based glucose sensing in the latter. NAD(P)H auto-
fluorescencemeasurements suggest that GLUTag and primary
L cells increase their metabolic rate in response to extracellu-
lar glucose elevation, consistent with our previous observation
that ATP concentrations in GLUTag cells are elevated upon
exposure to 1 mmol/l glucose [28]. NAD(P)H changes occur-
ring at glucose concentrations above ∼1 mmol/l would be
consistent with the recruitment of Glucokinase, which is
known to be expressed in enteroendocrine cells [7, 9,
29–31]. Glucokinase activity was demonstrable in GLUTag
cell extracts, and was responsive to the glucokinase activator,
GKA50. The observed S0.5 value (∼3 mmol/l) in the absence
of GKA50 is lower than the expected value of ∼5-8 mmol/
l [20], possibly reflecting incomplete inhibition of hexoki-
nases I–III or additional regulation of enzyme activity by
unknown factors in GLUTag cell extracts. GKA50 signifi-
cantly affected NAD(P)H autofluorescence at 3 mmol/l glu-
cose in GLUTag cells, demonstrating that glucokinase
exhibits at least some control over the metabolic flux in
L cells, but had only a small effect on glucose-stimulated
GLP-1 secretion from GLUTag cells and no effect on secre-
tion from primary cultures.
The present study demonstrates that metabolism plays at
best a minor role in glucose-stimulated GLP-1 secretion in
primary cultures, consistent with the finding that non-
metabolisable glucose analogues such as αMG are effective
stimuli of GLP-1 release in vivo and in vitro [10, 11, 16, 32].
Although phloretin abolished glucose accumulation in
GLUTag and primary L cells, its effect on glucose-
stimulated GLP-1 secretion was restricted to the cell line,
suggesting that glucose metabolism does not enhance secre-
tion in the context of a predominant SGLT1-mediated stim-
ulus. Future work should address whether the glucokinase/




























































































Fig. 6 Effect of genetic interference with SGLT1 action. (a) Ca2+
concentrations in Venus-positive L cells in colonic cultures, monitored
as the fura2 340/380 nm fluorescence ratio. Traces from a wild-type
and an Sglt1−/− mouse are shown after addition of glucose (10 mmol/l)
and glutamine (10 mmol/l). The vertical bar represents a change in the
fluorescence ratio of 0.1. (b) Mean normalised Ca2+ responses in
L cells recorded as in (a) from colonic cultures of control (white bars)
and Sglt1−/− (black bars) mice. Error bars represent 1 SEM and the
number of cells is given above the bars. *p<0.05, **p<0.01 vs
baseline and †p<0.05 between genotypes assessed using Student’s
t test. (c) Sglt1 expression in GLUTag cells transfected with Sglt1 or
scrambled (Con) siRNA, as determined using quantitative RT-PCR,
and normalised to β-actin. mRNA from four experiments were ana-
lysed for each bar. Data are presented as geometric mean and upper
SEM calculated from the log (base 2) data. Significance was analysed
by Student’s t test on the non-transformed ΔCt data; *p<0.05. (d)
GLP-1 secretion from GLUTag cells transfected with scrambled (white
bars) or Sglt1 siRNA (black bars). Cells were incubated in the absence
of additions (Con) or in the presence of glucose (10 mmol/l) or αMG
(100 mmol/l). Secretion was normalised to baseline measured in par-
allel on the same day. Error bars represent 1 SEM, and the number of
wells tested for each concentration is indicated above the bar. Signifi-
cance was calculated by two-way ANOVA and Bonferroni test; *p<0.05,
***p<0.001 vs baseline; ††p<0.01, †††p<0.001 between knock-down
and control
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L cells or enables modulation of GLP-1 secretion by neuro-
hormonal or alternative nutritional stimuli.
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